Última actualização :
19/11/2024
droga contra o câncer   Dacarbazine  
injetável
Estabilidade em soluções simples Estabilidade em misturas Factores que afectam a sua estabilidade Compatibilidade Método de administração Bibliografía pdf
   estrutura química  

Nomes comerciais nos diversos países   Nomes comerciais nos diversos países     

OS NOMES COMERCIAIS SÃO INDICATIVOS E OS EXCIPIENTES DA FORMULAÇÃO PODEM SER DIFERENTES CONFORME O PAÍS E FABRICANTE.

Acocarb México
Celdaz Índia, Peru
Dabaz Índia
Dacarb Índia, Peru
Dacarba Índia
Dacarbaz Turquia
Dacarbazin Austria, Hungria, Malásia, Polonia
Dacarbazina Argentina, Chilli, Colômbia, Equator, Espanha
Dacarbazine Australia, Bélgica, Canadá, Dinamarca, Estados Unidos de América, Gran-bretanha, Índia, Irã, Irlanda, nova Zelândia, Suècia
Dacarex Índia, Peru
Dacarin Índia
Dacarpalm Peru
Dacarzine Índia
Dacatic Finlandia
Dacin Suicia
Dacmed Índia
Daracina Colômbia
Deticene Arábia Saudita, França, Grècia, Itália, Países Baixos, Tunísia
Detilem México
Detimedac Alemanha, Colômbia
DTI Malásia
DTIC Australia, Austria, Estados Unidos de América, Gran-bretanha, nova Zelândia, Suècia
Fauldetic Portugal
Ifadac México
Oncocarbil Argentina, Equator, Peru
Tiferomed México
Bibliografía   injetável   Bibliografía : Dacarbazine  
tipo publicação
3 jornal Trissel LA, Martinez JF.
Compatibility of amifostine with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 2208-2212.
26 jornal Stewart JT, Warren FW, King DT, Venkateshwaran TG, Ponder GW, Fox JL.
Stability of ondansetron hydrochloride, doxorubicin hydrochloride, and dacarbazine or vincristine sulfate in elastomeric portable infusion devices and polyvinyl chloride bags.
Am J Health-Syst Pharm 1997 ; 54: 915-920.
40 jornal Dine T, Lebegue S, Benaji B, Gressier B, Segard V, Goudaliez F, Luyckx M, Brunet C, Mallevais ML, Kablan J, Cazin M, Cazin JC.
Stability and compatibility studies of four cytostatic agents (fluorouracil, dacarbazine, cyclophosphamide and ifosfamide) with PVC infusion bags.
Pharm Sci Communications 1994 ; 4: 97-101.
57 jornal Mayron D, Gennaro AR.
Stability and compatibility of granisetron hydrochloride in IV solutions and oral liquids and during simulated Y-site injection with selected drugs.
Am J Health-Syst Pharm 1996 ; 53: 294-304.
81 jornal Trissel LA, Martinez JF.
Compatibility of piperacillin sodium plus tazobactam with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 672-678.
84 jornal Trissel LA, Martinez JF.
Visual, turbidimetric, and particle-content assessment of compatibility of vinorelbine tartrate with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1994 ; 51: 495-499.
99 jornal Trissel LA, Martinez JF.
Compatibility of aztreonam with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1995 ; 52: 1086-1090.
169 jornal Trissel LA, Martinez JF.
Physical compatibility of melphalan with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1993 ; 50: 2359-2363.
184 jornal Stewart JT, Warren FW, King DT, Fox JL.
Stability of ondansetron hydrochloride and five antineoplasic medications.
Am J Health-Syst Pharm 1996 ; 53: 1297-1300.
244 jornal Trissel LA, Martinez JF.
Compatibility of filgrastim with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1907-1913.
248 jornal Trissel LA, Martinez JF.
Turbidimetric assessment of the compatibility of taxol with 42 other drugs during simulated Y-site injection.
Am J Hosp Pharm 1993 ; 50: 300-304.
249 jornal Trissel LA, Martinez JF.
Compatibility of thiotepa (lyophilized) with selected drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1996 ; 53: 1041-1045.
251 jornal Trissel LA, Gilbert DL, Martinez JF.
Compatibility of doxorubicin hydrochloride liposome injection with selected other drugs during simulated Y-site administration.
Am J Health-Syst Pharm 1997 ; 54: 2708-2713.
307 jornal Trissel LA, Martinez JF.
Compatibility of allopurinol sodium with selected drugs during simulated Y-site administration.
Am J Hosp Pharm 1994 ; 51: 1792-1799.
334 jornal Trissel LA, Tramonte SM, Grilley BJ.
Visual compatibility of ondansetron hydrochloride with selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 988-992.
335 jornal Trissel LA, Bready BB, Kwan JW, Santiago NM.
Visual compatibility of sargramostim with selected antineoplasic agents, anti-infectives, or other drugs during simulated Y-site injection.
Am J Hosp Pharm 1992 ; 49: 402-406.
353 jornal Lunn G, Sansone EB.
Reductive destruction of dacarbazine, procarbazine hydrochloride, isoniazid, and iproniazid.
Am J Hosp Pharm 1987 ; 44: 2519-2524.
492 jornal Trissel LA, Parks NPT, Santiago NM.
Visual compatibility of fludarabine phosphate with antineoplastic drugs, anti-infectives, and other selected drugs during simulated Y-site injection.
Am J Hosp Pharm 1991 ; 48: 2186-2189.
860 jornal Nelson RW, Young R, Lamnin M.
Visual incompatibility of dacarbazine and heparin.
Am J Hosp Pharm 1987 ; 44: 2028.
905 jornal Trissel LA, Martinez JF.
Screening teniposide for Y-site physical incompatibilities.
Hosp Pharm 1994 ; 29: 1010-1017.
1383 jornal Stevens MFG, Peatey L.
Photodegradation of solutions of the antitumour drug DTIC.
J Pharm Pharmacol 1978 ; 30: 47P.
1410 jornal Trissel LA, Martinez JF, Simmons M.
Compatibility of etoposide phosphate with selected drugs during simulated Y-site injection.
J Am Pharm Assoc 1999 ; 39: 141-145.
1501 jornal Beitz C, Bertsch T, Hannak D, Schrammel W, Einberger C, Wehling M.
Compatibility of plastics with cytotoxic drug solutions - comparison of polyethylene with other container materials.
Int J Pharm 1999 ; 185: 113-121.
1635 jornal El Aatmani M, Poujol S, Astre C, Malosse F, Pinguet F.
Stability of dacarbazine in amber glass vials and polyvinyl chloride bags.
Am J Health-Syst Pharm 2002 ; 59: 1351-1356.
2107 jornal Trissel LA, Zhang Y, Xu QA.
Physical and chemical stability of palonosetron hydrochloride with dacarbazine and with methylprednisolone sodium succinate during simulated Y-site administration.
Int J Pharm Compound 2006 ; 10: 234-236.
3266 Laboratório Lipomed Laboratories
Dacarbazine solutions: In Use stability of dacarbazine lipomed®
Lipomed 2011
3267 Laboratório Lipomed Laboratories
Dacarbazine Lipomed - Summary of Product Characteristics
Lipomed 2011
3540 Laboratório Heparin sodium - Summary of Product Characteristics.
Wockhardt 2010
3605 Laboratório Dacarbazine (Dacarbazine Lipomed®) - Résumé des caractéristiques du produit
Lipomed 2010

  Mentions Légales